An appeals court has reimposed restrictions on mifepristone in a closely watched case that could have a major impact on access to medication abortion
Late on Wednesday, an appellate court ruled partially in favor of anti-abortion advocates in a case challenging the Food and Drug Administration’s authorization of mifepristone, a key abortion drug.
The decision by the fifth circuit court of appeals imposes restrictions on mifepristone that include lowering the use of the drug to seven weeks of pregnancy instead of the current 10-week limit, and requiring in-person doctor visits for those looking to obtain the drug.
